JP2002528487A5 - - Google Patents

Download PDF

Info

Publication number
JP2002528487A5
JP2002528487A5 JP2000579200A JP2000579200A JP2002528487A5 JP 2002528487 A5 JP2002528487 A5 JP 2002528487A5 JP 2000579200 A JP2000579200 A JP 2000579200A JP 2000579200 A JP2000579200 A JP 2000579200A JP 2002528487 A5 JP2002528487 A5 JP 2002528487A5
Authority
JP
Japan
Prior art keywords
use according
group
well
drug delivery
delivery system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000579200A
Other languages
English (en)
Japanese (ja)
Other versions
JP5523647B2 (ja
JP2002528487A (ja
Filing date
Publication date
Priority claimed from US09/185,909 external-priority patent/US6174873B1/en
Application filed filed Critical
Publication of JP2002528487A publication Critical patent/JP2002528487A/ja
Publication of JP2002528487A5 publication Critical patent/JP2002528487A5/ja
Application granted granted Critical
Publication of JP5523647B2 publication Critical patent/JP5523647B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000579200A 1998-11-04 1999-11-01 アデノシンアナログの経口投与 Expired - Fee Related JP5523647B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/185,909 1998-11-04
US09/185,909 US6174873B1 (en) 1998-11-04 1998-11-04 Oral administration of adenosine analogs
PCT/US1999/025676 WO2000025758A1 (en) 1998-11-04 1999-11-01 Oral administration of adenosine analogs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010287707A Division JP5580726B2 (ja) 1998-11-04 2010-12-24 アデノシンアナログの経口投与

Publications (3)

Publication Number Publication Date
JP2002528487A JP2002528487A (ja) 2002-09-03
JP2002528487A5 true JP2002528487A5 (cg-RX-API-DMAC7.html) 2006-12-28
JP5523647B2 JP5523647B2 (ja) 2014-06-18

Family

ID=22682923

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000579200A Expired - Fee Related JP5523647B2 (ja) 1998-11-04 1999-11-01 アデノシンアナログの経口投与
JP2010287707A Expired - Fee Related JP5580726B2 (ja) 1998-11-04 2010-12-24 アデノシンアナログの経口投与

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010287707A Expired - Fee Related JP5580726B2 (ja) 1998-11-04 2010-12-24 アデノシンアナログの経口投与

Country Status (13)

Country Link
US (1) US6174873B1 (cg-RX-API-DMAC7.html)
EP (1) EP1126828B1 (cg-RX-API-DMAC7.html)
JP (2) JP5523647B2 (cg-RX-API-DMAC7.html)
AT (1) ATE427103T1 (cg-RX-API-DMAC7.html)
AU (1) AU774055B2 (cg-RX-API-DMAC7.html)
CA (1) CA2347913C (cg-RX-API-DMAC7.html)
DE (1) DE69940674D1 (cg-RX-API-DMAC7.html)
DK (1) DK1126828T3 (cg-RX-API-DMAC7.html)
ES (1) ES2322724T3 (cg-RX-API-DMAC7.html)
IL (2) IL142801A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA01004547A (cg-RX-API-DMAC7.html)
PT (1) PT1126828E (cg-RX-API-DMAC7.html)
WO (1) WO2000025758A1 (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050085937A (ko) 1997-12-11 2005-08-29 쉐링 악티엔게젤샤프트 고순도의 플루다라빈 포스페이트
WO1999036422A1 (en) 1998-01-14 1999-07-22 The Uab Research Foundation Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme
US6861448B2 (en) * 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
US6673827B1 (en) 1999-06-29 2004-01-06 The Uab Research Foundation Methods of treating fungal infections with inhibitors of NAD synthetase enzyme
US6174873B1 (en) * 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
ATE324888T1 (de) * 1999-06-14 2006-06-15 Cancer Rec Tech Ltd Krebstherapie
AU6234000A (en) * 1999-07-22 2001-02-13 Supergen, Inc. Methods for treating autoimmune diseases
AUPR018900A0 (en) * 2000-09-18 2000-10-12 Fh Faulding Pty Limited Pamidronate solution
WO2002009700A1 (en) * 2000-07-28 2002-02-07 Cancer Research Technology Limited Cancer treatment by combination therapy
AU2001284434A1 (en) * 2000-09-06 2002-03-22 Mitsubishi Pharma Corporation Granular preparations for oral administration
EP1671638A1 (en) * 2000-09-18 2006-06-21 F H Faulding & Co. Limited Disphosphonate solutions
US7629329B2 (en) 2001-06-04 2009-12-08 Tsi Health Sciences, Inc. Method for increasing muscle mass and strength through administration of adenosine triphosphate
WO2003020242A1 (en) * 2001-08-29 2003-03-13 Srl Technologies, Inc. Sustained release preparations
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
WO2003028712A2 (en) * 2001-09-28 2003-04-10 Universite Libre De Bruxelles Purinergic and pyrimidinergic receptor agonists for the treatment of activated cd4+ t lymphocyte-mediated immune diseases
US7037900B2 (en) * 2001-10-12 2006-05-02 Supergen, Inc. Composition and method for treating graft-versus-host disease
DE10164510A1 (de) * 2001-12-20 2003-07-10 Schering Ag Orale Fludara reinst Formulierung mit schneller Freisetzung des Wirkstoffes
US20030124178A1 (en) * 2001-12-28 2003-07-03 Haley Jeffrey T. Soft, adherent, soluble oral patch
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
EP1474144B1 (en) * 2002-02-01 2008-08-06 Pfizer Products Inc. Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
GB2386836B (en) * 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
CA2487070A1 (en) * 2002-05-24 2003-12-04 Sicor Inc. Aqueous fludarabine phosphate composition
US20080220107A1 (en) * 2002-09-03 2008-09-11 Pharmacure Health Care Ab Nasal spray apparatus
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
ITMI20022748A1 (it) * 2002-12-23 2004-06-24 Eurand Int Dispersioni solide stabilizzate di farmaco in un carrier organico e procedimento per la loro preparazione.
CA2520523C (en) * 2003-03-28 2011-10-11 Ivax Corporation Oral formulations of cladribine
WO2005025545A2 (en) * 2003-09-17 2005-03-24 Aderis Pharmaceuticals, Inc. Pharmaceutical formulation for controlled release of selodenoson
GB0321999D0 (en) * 2003-09-19 2003-10-22 Cancer Rec Tech Ltd Anti-cancer combinations
US20080221060A1 (en) * 2004-03-05 2008-09-11 Martyn Pritchard Therapeutic Compounds
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
WO2007023302A1 (en) * 2005-08-26 2007-03-01 Antisoma Plc Combinations comprising dmxaa for the treatment of cancer
US20070092559A1 (en) * 2005-10-24 2007-04-26 Jinghua Yuan Liquid dosage forms having enteric properties of delayed and then sustained release
DE102006006532B4 (de) 2006-02-10 2007-11-08 Biogenerics Pharma Gmbh Pharmazeutische Zubereitung
EP2057985B1 (en) * 2006-06-13 2013-10-16 Nippon Shinyaku Co., Ltd. Tablet coated with a polyvinyl alcohol copolymer
US8845627B2 (en) 2008-08-22 2014-09-30 Boston Scientific Scimed, Inc. Regulating pressure to lower temperature in a cryotherapy balloon catheter
WO2010133629A1 (en) * 2009-05-19 2010-11-25 Grindeks, A Joint Stock Company Stable pharmaceutical composition of fludarabine phosphate
EP2428201A1 (en) * 2010-09-08 2012-03-14 Merck Serono S.A. Oral administration of nucleoside monophosphates
WO2012097867A1 (en) 2011-01-18 2012-07-26 Synthon Bv Cladribine particles and pharmaceutical compositions comprising them
US8313774B1 (en) 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA7467B (en) * 1973-01-16 1974-11-27 J Voorhees Compositions and treatment of proliferative skin diseases with b2 agonists
US3923785A (en) 1974-04-22 1975-12-02 Parke Davis & Co (R)-3-(2-deoxy-{62 -D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo{8 4,5-d{9 {8 1,3{9 diazepin-8-ol
US3952741A (en) * 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
US4163839A (en) 1977-12-09 1979-08-07 Zaidan Hojin Biselbutsu Kagaku Kenkyu Kai Isocoformycin and a process for the production thereof
JPS57209226A (en) * 1981-06-18 1982-12-22 Yamasa Shoyu Co Ltd Antitumor activity intensifier
JPS57209225A (en) * 1981-06-18 1982-12-22 Yamasa Shoyu Co Ltd Antitumor activity intensifier
US5087618A (en) 1982-05-18 1992-02-11 University Of Florida Redox carriers for brain-specific drug delivery
JPS5920219A (ja) * 1982-07-26 1984-02-01 Shin Etsu Chem Co Ltd 腸溶性コ−テイング製剤の製造方法
JPS5951223A (ja) * 1982-09-17 1984-03-24 Sumitomo Chem Co Ltd 製剤組成物
US4713372A (en) 1984-03-16 1987-12-15 Warner-Lambert Company 2-chloropentostatin compound having adenosine diaminase inhibitory activity
US5254539A (en) * 1985-08-26 1993-10-19 U.S. Government, Dept. Of Health And Human Services, C/O National Institutes Of Health Method of treating HIV with 2',3'-dideoxyinosine
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4912092A (en) 1986-03-27 1990-03-27 The Regents Of The University Of California Methods for increasing extracellular adenosine and for stabilizing mast cells
US5459256A (en) 1987-04-17 1995-10-17 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Lipophilic, aminohydrolase-activated prodrugs
US5143661A (en) 1987-05-26 1992-09-01 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules
US5000886A (en) 1987-05-26 1991-03-19 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules and process of making the same
JPS649932A (en) * 1987-07-01 1989-01-13 Toyo Capsel Kk Soft capsule preparation using newly combined component as the base
US5521162A (en) 1987-08-26 1996-05-28 Merrell Pharmaceuticals Inc. Aristeromycin analogues of 4',5'-didehydro-5'-fluoro-adenosine and methods of treating neoplastic and viral disease conditions
US5132291A (en) 1989-01-24 1992-07-21 Gensia Pharmaceuticals, Inc. Antivirals and methods for increasing the antiviral activity of azt
WO1990014091A1 (en) * 1989-05-15 1990-11-29 The United States Of America, Represented By The Secretary, United States Department Of Commerce Method of treatment of hepatitis
US5561136A (en) 1990-12-13 1996-10-01 Merrell Pharmaceuticals Inc. Method of treating cancer by conjunctive therapy with N,N'-bis[ethylamino)propyl]-1,7-heptanediamine and a cytotoxic agent
NZ243567A (en) * 1991-07-22 1995-04-27 Bristol Myers Squibb Co Pharmaceutical oral formulation of a dideoxy purine nucleoside comprising the nucleoside together with a water-insoluble antacid buffering composition
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
JPH06316524A (ja) * 1992-09-11 1994-11-15 Naoyuki Inoue 抗エイズウイルス剤
US5633274A (en) * 1993-02-18 1997-05-27 President And Fellows Of Harvard College Cancer treatments
US5366960A (en) 1993-08-26 1994-11-22 Warner-Lambert Company Method of treating cerebral and cardiovascular disorders employing [R]3-(2-deoxy-β-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidaz 0-[4,5-d][1,3]diazepin-8-ol
US5635156A (en) 1993-09-13 1997-06-03 University Of Pittsburgh Non-lethal methods for conditioning a recipient for bone marrow transplantation
US5679648A (en) 1994-11-30 1997-10-21 The University Hospital Methods for the treatment and prevention of fungal infections by administration of 3'-deoxypurine nucleosides
US5663155A (en) 1994-11-30 1997-09-02 The University Hospital Compositions for the treatment of parasitic infections
JPH09100226A (ja) * 1995-10-03 1997-04-15 Sumitomo Pharmaceut Co Ltd 腸溶・徐放性コーティング製剤の製法
AU6771198A (en) * 1997-03-24 1998-10-20 Glaxo Group Limited Method for treating b-cell tumors with ara-g nucleoside derivatives
US6174873B1 (en) * 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
WO2012082533A1 (en) * 2010-12-14 2012-06-21 Hendrickson Usa, L.L.C. Head plate for vehicle axle

Similar Documents

Publication Publication Date Title
JP2002528487A5 (cg-RX-API-DMAC7.html)
JP5580726B2 (ja) アデノシンアナログの経口投与
CA2446712C (en) System for osmotic delivery of pharmaceutically active agents
JP2656933B2 (ja) 有効成分の投与のための医薬製剤
EP2543366B1 (en) Film preparation containing medicament with unpleasant taste
US5236713A (en) Preparation for intermittently releasing active agent applicable to oral cavity
IE921269A1 (en) Dosage forms comprising polymers comprising different¹molecular weights
CZ148396A3 (en) Preparation intended for controllable release of active compounds and the use thereof
WO2005023228A1 (en) Osmotic delivery of therapeutic compounds by solubility enhancement
EP0600033A1 (en) DOSAGE FOR THE RELEASE OF A FUEL IN A SHORT PERIOD.
NZ556775A (en) Controlled release complex formulation for oral, administration of medicine for diabetes and method for the preparation thereof
NZ505135A (en) Composition comprising a proton pump inhibitor (H+,K+-ATPase inhibitor) which provides two or more discrete release pulses in the small and/or large intestines
JP2006514058A (ja) 薬物の経口投与用の急速溶解フィルム
AU2002303897A1 (en) System for osmotic delivery of pharmaceutically active agents
CN1056057C (zh) 口服延缓释放的曲美他嗪药物组合物
JPS63243024A (ja) プソイドエフエドリンおよびブロムフエニラミンの投与用製剤
CN100563638C (zh) 硝苯地平控释片及其制备方法
Gupta et al. A review on: sustained release technology
KR960006062B1 (ko) 딜티아젬(diltiazem) 공급용의 제형(dosage form)
US4966769A (en) Method for delivering dosage form for diltiazem
JP2006528604A5 (cg-RX-API-DMAC7.html)
EP1191925B1 (en) Sustained release dosage form unit having latex coating and method of making the same
US20050025829A1 (en) Controlled drug release tablets
CN101642444B (zh) 单硝酸异山梨酯双速渗透泵型控释制剂及其制备方法
Mehta et al. Sustained release matrix tablet: an overview